CKD-371 is under clinical development by Chong Kun Dang Pharmaceutical and currently in Phase III for Type 2 Diabetes. According to GlobalData, Phase III drugs for Type 2 Diabetes have a 52% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how CKD-371’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CKD-371 is under development for the treatment of type 2 diabetes. It is a combination of D150, D759, and D745.
Chong Kun Dang Pharmaceutical overview
Chong Kun Dang Pharmaceutical (CKD Pharma), an affiliate of Chong Kun Dang, manufactures, distributes, imports and exports prescription drugs, OTC drugs, health supplements and consumer health products. The company works following therapeutic areas such as oncology, neurology and immunology and others. Its product portfolio includes prescription products for the entire segment and therapeutic classes; vitamins; shampoos; hair colours; aerosols; mat vaporizers and mosquito coils; and others. The company’s Chong Kun Dang Research Institute is characterized by three independent laboratories, namely, The New Drug Discovery Labs, The Technology Development Labs; and the Bio Research Labs. It has manufacturing facility in Cheonan City, South Korea. CKD Pharma is headquartered in Seoul, South Korea.
For a complete picture of CKD-371’s drug-specific PTSR and LoA scores, buy the report here.